论文部分内容阅读
目的:探讨布地奈德联合孟鲁司特钠对支气管哮喘患儿临床疗效与安全性的影响。方法:回顾性分析该医院2013年12月~2015年1月期间收治的62例支气管哮喘患儿,采用数字单双号的模式分为对照组(布地奈德)与研究组(布地奈德联合孟鲁司特钠),每组各31例。比较两组患儿的临床疗效与不良反应发生率。结果:研究组的治疗总有效率与不良反应发生率均明显优于对照组。结论:针对支气管哮喘患儿,采用布地奈德联合孟鲁司特钠联合治疗具有临床疗效显著、不良反应概率低的优势。
Objective: To investigate the effect of budesonide combined with montelukast on the clinical efficacy and safety of bronchial asthma in children. Methods: Sixty-two children with bronchial asthma admitted from December 2013 to January 2015 in our hospital were retrospectively analyzed. The patients were divided into control group (budesonide group) and study group (budesonide group) Montelukast sodium), 31 cases in each group. The clinical efficacy and incidence of adverse reactions in both groups were compared. Results: The study group’s total effective rate of treatment and adverse reactions were significantly better than the control group. Conclusion: In children with bronchial asthma, the combination of budesonide and montelukast sodium has obvious clinical curative effect and low probability of adverse reactions.